Drug Topics Newsletter

To view this email as a web page, click here.

From this month’s issue:

View the full issue here.

The Future of Pharmacy Automation

Affordable dispensing robots are opening new service opportunities for community pharmacies.

Hepatitis C: Resurgence Of A Silent Epidemic

3.5 million Americans are estimated to be living with chronic HCV infection, but half may not know.

Health System Specialty Pharmacies Enhance Services and Savings

A specialty pharmacy in the health system is convenient for patients and enhances care.

Why You Should Implement Enhanced Community Pharmacy Services

New study examines effective implementation of team-based care in community pharmacies.

Customized Central Fill to Fit Your Pharmacy & Your Business

With a system designed to meet your needs today and as you add services in the future; you can grow revenue, reduce costs, maximize inventory throughput, and free up staff time for clinical interventions with McKesson’s Central Fill Solutions.

Changing Healthcare Environment Prompts New Roles for Pharmacists

Changes fueled by the 2003 Medicare Prescription Drug Improvement and Modernization Act.

Gottlieb on Creating Space for Opportunity and Innovation

At the 2019 Asembia Specialty Pharmacy Summit, former FDA Commissioner Scott Gottlieb discussed advances within the agency during his tenure.

The Redefinition of Pharmacy Jobs

Some jobs may disappear while others evolve and require further training.

How Pharmacists Benefit Value-Based Programs

Value-based programs emphasize better care, enhanced health, and lower costs.

Vaccination Pipeline

Exciting and upcoming developments, years in the making.

New Drug Review: Erdafinitib

First oral drug for advanced or metastatic bladder cancer.

Guest Columns

New Organization Aims to Get the Medications Right

Comprehensive medication management may lower costs and improve lives.

Hiring Approaches

Neither your gut nor peer advice will get you the caliber people you need.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT